Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 25;14:1192118. doi: 10.3389/fneur.2023.1192118

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Lin, Dong, Yu and Huang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Brain MRI revealed hyperintense of the corpus callosum on T2 sequence MRI (A) and diffusion-weighted MRI (B) before immunotherapy. MRI postcontrast axial T1-weighted scans (C) and sagittal T1-weighted scans (D) showed leptomeningeal enhancement of the pons and medulla before immunotherapy. Sagittal T2 sequence MRI showed no hyperintensities throughout the cervical spinal cord and thoracic spinal cord (E). The high signal intensity of the corpus callosum on diffusion-weighted MRI disappeared after immunotherapy (F). MRI postcontrast axial T1-weighted scans and sagittal T1-weighted scans showed that leptomeningeal enhancement of the pons and medulla completely disappeared after immunotherapy (G, H). Arrows indicate leptomeningeal enhancement. Oval shape indicates the lesion in the corpus callosum.